In 1943, Swiss chemist Albert Hofmann took the first LSD trip.
With a high demand for psychedelic facilitators, Cybin Inc.
Breaking Convention 2023 will see a panel of experts join together to discuss the benefits and risks of ketamine-assisted psychotherapy as the treatment begins to gain...
Patients with Major Depressive disorder (MDD) have been shown to achieve remission within three months following treatment with SPL026 combined with supportive therapy in Small Pharma’s...
In a partnership that has been described as “an important step to reintroduce psychedelics into society”, Dimensions and the New Health Club are joining together to...
With years of experience in developing cannabinoid medicines, Australia-based MGC Pharmaceuticals will now be branching into psychedelic medicine development.
The Dutch Parliament has established an independent State Commission to research the legal status of MDMA and provide advice on its medical use.
Study participants demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the...
Beckley Psytech has initiated a Phase IIa study of its 5-MeO-DMT candidate – BPL-003 – for Alcohol Use Disorder (AUD), which will take place at King’s...
While psychedelic research has, to date, largely focused on mathematical modelling and resting-state neuroimaging, cognitive neuroscientists are bringing new rigour to the field through the use...